N/A
Completed N=742,670
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
Source: ClinicalTrials.gov NCT05768945 ↗Enrolled (actual)
742,670
Serious AEs
—
Results posted
Nov 2025
Primary outcomePrimary: Time to Dementia Onset — 4.40; 6.06; 4.69; 6.71 Incidence rate per 1000 person year
Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Dementia Onset |
4.40; 6.06; 4.69; 6.71; 2.80; 10.24 | — |
Eligibility Criteria
Please see https://drive.google.com/drive/folders/1VRjPaaelXFyBbA5gV6pwB\_ijSIMyIJ4N?usp=share\_link or Appendix A(https://drive.google.com/drive/folders/1OgKQlxsJi9UWRDd3Kbaux\_8adngoSnZY?usp=sharing) for full code and algorithm definitions.
Medicare timeframe: 2008 to 2019 (end of data availability).
Inclusion Criteria
- 1. Aged >/= 65 years on the index date
- 2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
- 3. Diagnosis code for type 2 diabetes measured 365 days prior to drug initiation
Exclusion Criteria
- 1. Prior history of dementia measured anytime prior to cohort entry date
- 2. Prior history of nursing home admission in the 365 days prior to the cohort entry date
- 3. Prior use of any GLP receptor agonists (semaglutide, exenatide, liraglutide, albiglutide, dulaglutide, lixisenatide) or DPP4 inhibitors
- 4. Prior use of Semaglutide or DPP4 inhibitors concomitantly on index date
Data sourced from ClinicalTrials.gov (NCT05768945). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.